Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Novavax (NASDAQ:NVAX) traded higher in the premarket on Wednesday after the Maryland-based biotech reported ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Nuvaxovid lasts six months under the same conditions. “The Novavax vaccine is much less demanding,” Fei Wen, a chemical engineer at the University of Michigan, told The Daily Beast.

Trade Name in the U.S. The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA). Authorized Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given ...

Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses.